The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 03, 2019
Filed:
Dec. 28, 2017
Applicant:
Taiwan Mitochondrion Applied Technology Co., Ltd, Zhubei, Hsinchu County, TW;
Inventors:
Shinn-Zong Lin, Taichung, TW;
Horng-Jyh Harn, Taichung, TW;
Shih-Ping Liu, Taichung, TW;
Han-Chung Cheng, Zhubei, TW;
Chi-Tang Tu, Zhubei, TW;
Assignee:
TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD, Zhubei, Hsinchu County, TW;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/07 (2010.01); C12N 5/071 (2010.01); C12N 5/079 (2010.01); C12N 5/0793 (2010.01); C12N 5/0797 (2010.01); C12N 5/0735 (2010.01); C12N 5/074 (2010.01); C12N 5/077 (2010.01); C12N 5/0775 (2010.01); C12N 5/0789 (2010.01); G01N 33/567 (2006.01); A01N 1/00 (2006.01); A61K 48/00 (2006.01); A01N 63/00 (2006.01); A61K 35/28 (2015.01); C07K 14/575 (2006.01); A61K 9/00 (2006.01); A61P 25/16 (2006.01); A61K 38/18 (2006.01); A01K 67/027 (2006.01); A61K 35/50 (2015.01); A61K 35/35 (2015.01); A61K 36/232 (2006.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A01K 67/027 (2013.01); A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 38/185 (2013.01); A61P 25/16 (2018.01); C07K 14/575 (2013.01); C12N 5/0667 (2013.01); A61K 35/35 (2013.01); A61K 35/50 (2013.01); A61K 36/232 (2013.01); C12N 2500/16 (2013.01); C12N 2500/30 (2013.01); C12N 2500/38 (2013.01); C12N 2500/76 (2013.01); C12N 2501/11 (2013.01); C12N 2501/999 (2013.01); C12N 2506/13 (2013.01); C12N 2506/1369 (2013.01);
Abstract
A cell for treating neurodegenerative disease treated withextract is provided. The pharmaceutical composition comprises the cell for treating neurodegenerative disease and can significantly increase and recover the number of dopaminergic neurons to achieve the goal for treating neurodegenerative disease.